Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy - Institut Pasteur Access content directly
Journal Articles Current Opinion in Virology Year : 2022

Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy

Abstract

Rabies is a severe viral infection that causes an acute encephalomyelitis, which presents a case fatality of nearly 100% after the manifestation of neurological clinical signs. Rabies can be efficiently prevented with post-exposure prophylaxis (PEP), composed of vaccines and anti-rabies immunoglobulins (RIGs); however, no treatment exists for symptomatic rabies. The PEP protocol faces access and implementation obstacles in resource-limited settings, which could be partially overcome by substituting RIGs for monoclonal antibodies (mAbs). mAbs offer lower production costs, consistent supply availability, long-term storage/stability, and an improved safety profile. Here we summarize the key features of the different available mAbs against rabies, focusing on their application in PEP and highlighting their potential in a novel therapeutic approach.
Fichier principal
Vignette du fichier
1-s2.0-S1879625722000116-main.pdf (1.48 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

pasteur-03827722 , version 1 (24-10-2022)

Licence

Identifiers

Cite

Guilherme Dias de Melo, Jan Hellert, Rajesh Gupta, Davide Corti, Hervé Bourhy. Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy. Current Opinion in Virology, 2022, 53, pp.101204. ⟨10.1016/j.coviro.2022.101204⟩. ⟨pasteur-03827722⟩

Collections

PASTEUR ANR
11 View
289 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More